Journal article
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers
Abstract
BackgroundTasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment. This study aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors.Patients and MethodsThis early stopping design, open-label, proof-of-concept clinical trial evaluated the clinical activity of tasquinimod in four independent …
Authors
Escudier B; Faivre S; Van Cutsem E; Germann N; Pouget J-C; Plummer R; Vergote I; Thistlethwaite F; Bjarnason GA; Jones R
Journal
Targeted Oncology, Vol. 12, No. 5, pp. 655–661
Publisher
Springer Nature
Publication Date
10 2017
DOI
10.1007/s11523-017-0525-2
ISSN
1776-2596